drugset / Trial / NCT01393951
A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This trial is designed as a blinded, randomized and parallel group study to investigate the clinically recommended dosage for ASP7374 based on the comparison of the immunogenicity and safety among two doses of subcutaneous ASP7374 and one dose of intramuscular ASP7374 in healthy adults.
Timeline
- Start
- 2011-05
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASP7374 | Vaccine | — | Subcutaneous |
Indications
No indication recorded.